Abstract：
Hemangiosarcoma is an aggressive tumour that most frequently occurs in larger, middle-aged dogs of certain breeds. The spleen is the most commonly affected organ. The aim of this prospective therapy study was to evaluate the clinical effect of autologous, monocyte-derived dendritic cell (DC) therapy in canine hemangiosarcoma stage II after splenectomy. Dogs (n=452) diagnosed with splenic hemangiosarcoma that underwent splenectomy were enrolled. Of these, 42 dogs with stage II entered the DC therapy study. The median survival time for the total group of 42 dogs was 203 days. The median survival for the group (n=34) that received the full DC therapy (≥3 vaccines) was 256 days, with a 29 % one-year survival rate and a hazard ratio of 0.30, adjusted to age and bodyweight (P=0.010). We further observed a significant increase in DC yield after each application and demonstrated that DC yield at the beginning of treatment is significantly related to patient survival. While further evidence is needed, we conclude that autologous, monocyte-derived DC therapy is a viable alternative to standard treatment methods of canine splenic stage II hemangiosarcoma.
摘要：
血管肉瘤是一种侵袭性肿瘤，最常发生在较大的，某些品种的中年狗。最常见的器官是脾脏。这项前瞻性治疗试验的目的是评估自体治疗的临床效果，脾切除术后II期犬血管肉瘤的单核细胞衍生树突状细胞（DC）治疗。纳入诊断为脾血管肉瘤并接受脾切除术的犬（n=452）。其中,42只II期的狗进入DC治疗试验。总共42只狗的中位存活时间为203天。接受完全DC治疗（≥3种疫苗）的组的中位生存期为256天，根据年龄和体重调整后，一年生存率为29％，风险比为0.30（P=0.010）。我们进一步观察到每次施用后DC产量的显著增加,并证明在治疗开始时DC产量与兽医患者存活显著相关。虽然还需要进一步的证据,我们得出的结论是自体的，单核细胞来源的DC治疗是犬脾血管肉瘤标准治疗的可行替代方法。
